BR112022019155A2 - Aril piperidinas como moduladores da monoacilglicerol lipase - Google Patents

Aril piperidinas como moduladores da monoacilglicerol lipase

Info

Publication number
BR112022019155A2
BR112022019155A2 BR112022019155A BR112022019155A BR112022019155A2 BR 112022019155 A2 BR112022019155 A2 BR 112022019155A2 BR 112022019155 A BR112022019155 A BR 112022019155A BR 112022019155 A BR112022019155 A BR 112022019155A BR 112022019155 A2 BR112022019155 A2 BR 112022019155A2
Authority
BR
Brazil
Prior art keywords
modulators
aryl
disorders
monoacylglycerol lipase
methods
Prior art date
Application number
BR112022019155A
Other languages
English (en)
Inventor
K Ameriks Michael
B Berry Cynthia
Biró Krisztián
Garcia-Reynaga Pablo
V Samant Andrew
S Wade Warren
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022019155A2 publication Critical patent/BR112022019155A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ARIL PIPERIDINAS COMO MODULADORES DA MONOACILGLICEROL LIPASE. A presente invenção refere-se a compostos de aril piperidina da Fórmula (I), e sais, isótopos, N-óxidos, solvatos e estereoisômeros farmaceuticamente aceitáveis dos mesmos, composições farmacêuticas que os contêm, e métodos de uso destes, incluindo métodos para tratamento de estados doentios, distúrbios e condições associados à modulação da MGL, como aqueles associados a dor, distúrbios psiquiátricos, distúrbios neurológicos (incluindo, mas não se limitando a, distúrbio depressivo maior, depressão resistente a tratamento, depressão por ansiedade, distúrbios do espectro de autismo, síndrome de Asperger, distúrbio bipolar), cânceres e condições oculares: ; em que R2a, R2b, R3 e R4 são os definidos no presente documento.
BR112022019155A 2020-03-26 2021-03-25 Aril piperidinas como moduladores da monoacilglicerol lipase BR112022019155A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000282P 2020-03-26 2020-03-26
PCT/EP2021/057820 WO2021191384A1 (en) 2020-03-26 2021-03-25 Aryl piperidines as monoacylglycerol lipase modulators

Publications (1)

Publication Number Publication Date
BR112022019155A2 true BR112022019155A2 (pt) 2022-12-06

Family

ID=75302569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019155A BR112022019155A2 (pt) 2020-03-26 2021-03-25 Aril piperidinas como moduladores da monoacilglicerol lipase

Country Status (10)

Country Link
US (2) US11787798B2 (pt)
EP (1) EP4126840A1 (pt)
JP (1) JP7729832B2 (pt)
KR (1) KR20220158060A (pt)
CN (1) CN115362151B (pt)
AU (1) AU2021243726A1 (pt)
BR (1) BR112022019155A2 (pt)
CA (1) CA3177058A1 (pt)
MX (1) MX2022011901A (pt)
WO (1) WO2021191384A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021220539A1 (en) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
MX2022011903A (es) 2020-03-26 2023-01-11 Janssen Pharmaceutica Nv Azaspirociclos como moduladores de monoacilglicerol lipasa.
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CN115362151B (zh) 2020-03-26 2025-02-11 詹森药业有限公司 作为单酰基甘油脂肪酶调节剂的芳基哌啶
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078376A1 (en) * 2002-03-13 2003-09-25 Schering Corporation Nk1 antagonists
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8435977B2 (en) * 2009-04-22 2013-05-07 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
US8987247B2 (en) 2011-09-30 2015-03-24 Janssen Pharmaceutica Nv Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
CN108137562B (zh) * 2015-08-04 2021-11-30 耶路撒冷希伯来大学伊森姆研究发展有限公司 吡唑嘧啶衍生物及其用途
US10610520B2 (en) * 2016-03-31 2020-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
MY194647A (en) * 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
JP7189143B2 (ja) 2017-09-29 2022-12-13 武田薬品工業株式会社 複素環化合物
WO2020211798A1 (zh) 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
AU2021220539A1 (en) 2020-02-10 2022-10-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
MX2022011903A (es) 2020-03-26 2023-01-11 Janssen Pharmaceutica Nv Azaspirociclos como moduladores de monoacilglicerol lipasa.
CA3176113A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators
CN115362151B (zh) * 2020-03-26 2025-02-11 詹森药业有限公司 作为单酰基甘油脂肪酶调节剂的芳基哌啶

Also Published As

Publication number Publication date
MX2022011901A (es) 2023-01-04
US20220363679A1 (en) 2022-11-17
JP2023518515A (ja) 2023-05-01
US11787798B2 (en) 2023-10-17
US20240092781A1 (en) 2024-03-21
CN115362151B (zh) 2025-02-11
KR20220158060A (ko) 2022-11-29
EP4126840A1 (en) 2023-02-08
CN115362151A (zh) 2022-11-18
WO2021191384A1 (en) 2021-09-30
CA3177058A1 (en) 2021-09-30
JP7729832B2 (ja) 2025-08-26
AU2021243726A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
BR112022019211A2 (pt) Azaspirociclos como moduladores de lipase de monoacilglicerol
BR112022019178A2 (pt) Aminociclobutanos como moduladores da monoacilglicerol lipase
BR112022019077A2 (pt) Moduladores da monoacilglicerol lipase
MX2022011901A (es) Arilo piperidinas como moduladores de monoacilglicerol lipasa.
SA521421575B1 (ar) مُعدلات ليباز أُحادِيُّ الجلِيسِريد
BR112022015116A2 (pt) Moduladores de monoacilglicerol lipase
MX2023003240A (es) Moduladores de monoacilglicerol lipasa de ciclobutilamida.
GEAP202416430A (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
AR053110A1 (es) Analogos de aminopirazina para tratar el glaucoma y otras enfermedades y afecciones mediadas por la rho-quinasa
AR030533A1 (es) Compuestos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas, composicion farmaceutica, procedimiento de tratamiento intermediario
PE20091756A1 (es) Derivados de pirazolopirimidinona como moduladores de la pde9a
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
AR038483A1 (es) Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides
BR112023022524A2 (pt) Moduladores de molécula pequena de atividade de glicocerebrosidase e usos dos mesmos
KR100570374B1 (ko) 5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물
AR123154A1 (es) Derivados heterocíclicos sustituidos de pirazolo[1,5-a]pirimidina farmacológicamente activos
PE20242105A1 (es) Moduladores de micromoleculas de la actividad de la glucocerebrosidasa y usos de estos
AR057887A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
BRPI0608032A2 (pt) composição para o cuidado do cabelo e/ou do couro cabeludo, método para tratar e/ou prevenir as afecções inflamatórias da pele, uso de um composto de amino-oxo-indol-ilideno e uso de uma composição
BR9905634A (pt) Piperidinas 4-substituìdas, composições farmacêuticas e processo para tratamento de desordens do sistema nervoso central em seres humanos
BRPI0410613A (pt) preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
PE20250932A1 (es) Compuestos, composiciones y metodos de uso de los mismos
PE20251079A1 (es) Compuestos de triazina y usos de los mismos
PE20251399A1 (es) Derivados de tetrahidrotiazepina biciclicos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements